Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors
PURPOSE: New tumor therapies like immune checkpoint inhibitors and small molecule inhibitors of MEK and BRAF have increased the patient's survival rate but can be burdened with severe side-effects including uveitis. Here, we show the spectrum, treatment, and outcome of uveitis types induced by tumor treatment.
METHODS: In this retrospective study, we have included 54 patients from different centers who were developing uveitis under tumor therapy. A 16-item questionnaire was analyzed for type, treatment, and outcome of uveitis and type of tumor treatment, which we have correlated here.
RESULTS: Irrespective of the tumor treatment, most patients developed anterior uveitis. All patients received corticosteroids and some additional immunosuppressive treatments. Cessation of tumor therapy was necessary only in a minority of cases.
CONCLUSIONS: Ocular autoimmunity should be differentiated from toxic effects of cancer treatment and timely recognized since it can be generally well controlled by anti-inflammatory treatment, preserving the patient's vision without cessation of the tumor treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - 30(2022), 7-8 vom: 13. Okt., Seite 1588-1594 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thurau, Stephan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune disease |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09273948.2021.1910850 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325345139 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325345139 | ||
| 003 | DE-627 | ||
| 005 | 20231225192237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2021.1910850 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325345139 | ||
| 035 | |a (NLM)33983102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thurau, Stephan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: New tumor therapies like immune checkpoint inhibitors and small molecule inhibitors of MEK and BRAF have increased the patient's survival rate but can be burdened with severe side-effects including uveitis. Here, we show the spectrum, treatment, and outcome of uveitis types induced by tumor treatment | ||
| 520 | |a METHODS: In this retrospective study, we have included 54 patients from different centers who were developing uveitis under tumor therapy. A 16-item questionnaire was analyzed for type, treatment, and outcome of uveitis and type of tumor treatment, which we have correlated here | ||
| 520 | |a RESULTS: Irrespective of the tumor treatment, most patients developed anterior uveitis. All patients received corticosteroids and some additional immunosuppressive treatments. Cessation of tumor therapy was necessary only in a minority of cases | ||
| 520 | |a CONCLUSIONS: Ocular autoimmunity should be differentiated from toxic effects of cancer treatment and timely recognized since it can be generally well controlled by anti-inflammatory treatment, preserving the patient's vision without cessation of the tumor treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRAF inhibitor | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a MEK inhibitor | |
| 650 | 4 | |a autoimmune disease | |
| 650 | 4 | |a eye | |
| 650 | 4 | |a ocular inflammation | |
| 650 | 4 | |a uveitis | |
| 700 | 1 | |a Engelke, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a McCluskey, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Symes, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Whist, Eline |e verfasserin |4 aut | |
| 700 | 1 | |a Teuchner, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Haas, Gertrud |e verfasserin |4 aut | |
| 700 | 1 | |a Allegri, Pia |e verfasserin |4 aut | |
| 700 | 1 | |a Cimino, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Bolletta, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Miserocchi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Marinella |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jeany Q |e verfasserin |4 aut | |
| 700 | 1 | |a Heiligenhaus, Arnd |e verfasserin |4 aut | |
| 700 | 1 | |a Wildner, Gerhild |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 30(2022), 7-8 vom: 13. Okt., Seite 1588-1594 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2022 |g number:7-8 |g day:13 |g month:10 |g pages:1588-1594 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2021.1910850 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2022 |e 7-8 |b 13 |c 10 |h 1588-1594 | ||